ZyVersa Therapeutics, Inc. (ZVSA)
(Delayed Data from NSDQ)
$2.47 USD
+0.09 (3.78%)
Updated Sep 17, 2024 03:59 PM ET
After-Market: $2.43 -0.04 (-1.62%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for ZyVersa Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -98.30 | -14.12 | -8.08 | NA | NA |
Depreciation/Amortization & Depletion | 11.91 | 0.05 | 0.33 | NA | NA |
Net Change from Assets/Liabilities | 2.60 | 5.66 | -1.02 | NA | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | NA | NA |
Other Operating Activities | 75.07 | 3.53 | 3.70 | NA | NA |
Net Cash From Operating Activities | -8.72 | -4.89 | -5.08 | NA | NA |
Property & Equipment | 0.00 | 0.00 | 0.00 | NA | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | NA | NA |
Investments | 0.00 | 0.00 | 0.00 | NA | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | NA | NA |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | NA | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 8.38 | 1.96 | 0.00 | NA | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | NA | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 5.23 | NA | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | NA | NA |
Other Financing Activities | -2.42 | -0.10 | 0.00 | NA | NA |
Net Cash from Financing Activities | 5.96 | 1.87 | 5.23 | NA | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | NA | NA |
Net Change In Cash & Equivalents | -2.76 | -3.02 | 0.15 | NA | NA |
Cash at Beginning of Period | 5.90 | 9.62 | 0.17 | NA | NA |
Cash at End of Period | 3.14 | 6.60 | 0.33 | NA | NA |
Diluted Net EPS | -1,089.70 | -937.06 | NA | NA | NA |
Fiscal Year End for ZyVersa Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -5.59 | -2.83 | -98.30 | -84.96 | -82.06 |
Depreciation/Amortization & Depletion | 0.01 | 0.00 | 11.91 | 11.90 | 11.90 |
Net Change from Assets/Liabilities | -0.59 | -1.26 | 2.60 | 4.00 | 2.30 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.48 | 0.31 | 75.07 | 63.12 | 62.86 |
Net Cash From Operating Activities | -5.69 | -3.78 | -8.72 | -5.93 | -5.00 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.67 | 2.67 | 8.38 | 3.38 | 0.54 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -2.42 | -1.77 | -1.22 |
Net Cash from Financing Activities | 2.67 | 2.67 | 5.96 | 1.61 | -0.68 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -3.02 | -1.10 | -2.76 | -4.32 | -5.67 |
Cash at Beginning of Period | 3.14 | 3.14 | 5.90 | 5.90 | 5.90 |
Cash at End of Period | 0.12 | 2.03 | 3.14 | 1.58 | 0.23 |
Diluted Net EPS | -3.31 | -4.53 | 770.44 | -31.47 | -1,692.31 |